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Introduction: Preoperative treatment and adequate surgery increase local control in rectal cancer.
However, modalities and indications for neoadjuvant treatment may be controversial. Aim of this study
was to assess the trends of preoperative treatment and outcomes in patients with rectal cancer included
in the Rectal Cancer Registry of the Spanish Associations of Surgeons.
Method: This is a STROBE-compliant retrospective analysis of a prospective database. All patients
operated on with curative intention included in the Rectal Cancer Registry were included. Analyses were
performed to compare the use of neoadjuvant/adjuvant treatment in three timeframes: I)2006e2009; II)
2010e2013; III)2014e2017. Survival analyses were run for 3-year survival in timeframes I-II.
Results: Out of 14,391 patients,8871 (61.6%) received neoadjuvant treatment. Long-course chemo/
radiotherapy was the most used approach (79.9%), followed by short-course radiotherapy ± chemo-
therapy (7.6%). The use of neoadjuvant treatment for cancer of the upper third (15-11 cm) increased over
time (31.5%vs 34.5%vs 38.6%,p¼ 0.0018). The complete regression rate slightly increased over time (15.6%
vs 16% vs 18.5%; p¼ 0.0093); the proportion of patients with involved circumferential resection margins
(CRM) went down from 8.2% to 7.3%and 5.5% (p¼ 0.0004). Neoadjuvant treatment significantly
decreased positive CRM in lower third tumors (OR 0.71, 0.59e0.87, Cochrane-Mantel-Haenszel
P¼ 0.0008). Most ypN0 patients also received adjuvant therapy. In MR-defined stage III patients, pre-
operative treatment was associated with significantly longer local-recurrence-free survival (p< 0.0001),
and cancer-specific survival (p< 0.0001). The survival benefit was smaller in upper third cancers.
Conclusion: There was an increasing trend and a potential overuse of neoadjuvant treatment in cancer of
the upper rectum. Most ypN0 patients received postoperative treatment. Involvement of CRM in lower
third tumors was reduced after neoadjuvant treatment. Stage III and MRcN þ benefited the most.
© 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
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Neoadjuvant treatment for rectal cancer combined with proper
total mesorectal excision (TME) has been shown to increase local
control after curative resection. Over the last years, indications as
well as treatment modalities have greatly evolved. A significant
variation on them can also be observed when comparing different
guidelines for the management of rectal cancer [1e3].
The benefits of neoadjuvant treatment come at the cost of
several side effects [4e6], which are often underplayed, due to the
short-term outcomes reported in most trials [7]. In addition, an
excess of noncancer deaths after neoadjuvant treatment has been
reported [7,8]. This could be important, at a time when there is a
trend for an increased use of neoadjuvant treatment for rectal
cancer.
The need of assessing and improving the outcomes of rectal
cancer treatment, led to the set-up of several multicentric registries
and initiatives, aimed at capturing data on patients treated over the
last decades. Examples include the Norwegian Registry [9] and the
Optimizing Surgical Treatment of Rectal Cancer (OSTRiCh) Con-
sortium in the US [10]. Similarly, the Spanish Association of Sur-
geons (AEC) [11] started in 2006 a national educational project to
implement TME across the country, by means of an online database
of patients treated for primary rectal cancer. The registry captured
data on neoadjuvant and adjuvant treatment, as well as patholog-
ical and survival outcome. This article aims at reporting on the
trends of use and oncological results of neoadjuvant treatment for
rectal cancer over tenyears in the context of a quality-improvement
initiative.
Material and methods
This is a retrospective analysis of a prospective national data-
base. The report complies with the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) statement [12].
The AEC Registry followed the same principles of the Norwegian
Registry [9]. The eventual aims were to improve the quality of
treatment incorporating TME and multimodal treatment for pa-
tients with rectal cancer nationally.
Between 2006 and 2017, 105 hospitals joined the registry with
nearly 19,000 patients. All patients, who underwent surgery with
curative intent between 2006 and 2017 were evaluated for inclu-
sion. The analyses were conducted after obtaining Ethical Com-
mittee approval.
Inclusion criteria
Patients were excluded if they did not receive surgery, if surgery
was with palliative intent or if it did not involve resection of the
tumor, and if they had metastatic disease at presentation.
Definitions
Neoadjuvant treatment was captured in the database. Data on
adjuvant treatment were also collected. Patients were stratified in
three timeframes: I) 2006e2009; II) 2010e2013; III) 2014e2017.
Local recurrence (LR) was defined as peritoneal, pelvic, or perineal
tumor re-growth after curative resection. Distant recurrences were
defined as evidence of disease in any other location. Cancer-specific
survival (CSS) was defined as death as a consequence of cancer. For
overall survival (OS), death for any cause was assessed.
Preoperative assessment was performed by means of CT, MRI,Please cite this article as: Pellino G et al., Trends and outcome of neoadju
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https://doi.org/10.1016/j.ejso.2020.04.056endoscopy, and endorectal ultrasonography, as available. A rigid
proctoscopy was used to define tumour height. Definitions and
scope of the registry have been previously reported in details
[13e15].
Endpoints
The primary endpoint was the rate of patients that received
neoadjuvant treatment.
Secondary endpoints included the type of treatment used, the
trends of treatment over time, and likeliness of receiving post-
operative treatment.
Sub-analyses correlated neoadjuvant treatment with pathologic
regression and rates of circumferential margin (CRM) involvement.
Additional analyses included 3-year CSS, OS, LR-free survival,
and disease-free survival (DFS) after neoadjuvant treatment in the
timeframes I (2006e2009) and II (2010e2013).
Statistical analysis
Continuous variables are reported asmedian (range), categorical
variables are reported as number with percentage (%).
Categorical variables were comparedwith Fisher's exact test and
Chi Square Test for trends as appropriate, whereas continuous
variables were compared with Mann-Whitney U and Kruskal-
Wallis test.
The Cochrane-Mantel-Haenszel test was used to assess the
global risk of CRM involvement and positive resection margins in
the different timeframes, stratifying patients according to whether
a neoadjuvant therapy was used or not [16]. Results are reported as
Odds Ratio (OR) with 95% confidence intervals (95%CI). OR>1 is
associated with increased risk.
Binomial logistic regression analyses were run to identify factors
associated with neoadjuvant and adjuvant treatment. Only patients
that underwent preoperative MRI were included in the regression
models, on condition that adequate quantity and quality of infor-
mation was available. The variables included in the regression for
neoadjuvant treatment included sphincter complex status, T stage
at MRI (MRcT) and N stage at MRI (MRcN), gender, status of the
mesorectal fascia (MRF), tumor height, age, and treatment time-
frame. In the regression for adjuvant treatment, pathologic out-
comes were also included along with intraoperative perforation,
complications, and preoperative treatment.
Kaplan-Meier survival curves were generated to assess survival,
and LogRank test was used for comparisons. Cox test was used to
estimate the Hazard Ratio (HR). Sensitivity analyses included sur-
vival in MRcT3-4 patients and radiological Stage III patients. Sub-
analyses according to MRcN and cancer height were performed.
Only patients with available data on preoperative MRI scan were
included.
The statistical Package for Social Sciences (SPSS version 24.0.0;
IBM SPSS statistics, IBM Corporation, Armonk, NY) was used for the
analyses. P values< 0.05 were considered statistically significant.
Results
Overall, data on 18,782 patients were uploaded on the Registry.
After removing 954 patients that did not receive surgery or for
whom data were not available, those who underwent emergency
surgery, surgery with palliative intent, surgery without resection,
pelvic exenteration, local excision, proctocolectomy, transanal TME,
and patients with Stage IV disease, a total of 14,391 patients fit invant treatment for rectal cancer: A retrospective analysis and critical
anish Rectal Cancer Project, European Journal of Surgical Oncology,
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Table 1.
Type of neoadjuvant treatment
A total of 8871 (61.6%) patients received neoadjuvant treatment.
This consisted of long course radiation therapy (RT) or chemo-
radiation therapy (CRT) in 7377 (79.9%), short course RT with or
without chemotherapy in 674 (7.6%), chemotherapy followed by RT
in 600 (6.8%), chemotherapy alone in 93 (1%), and other modalities
in 126 (1.4%). Preoperative assessment included MRI in 94.2% of
patients that received neoadjuvant treatment.
Trends of neoadjuvant treatment over time
Patients receiving neoadjuvant treatment went slightly up from
58.2% during the first timeframe to 62.5% and 62.6% in the more
recent timeframes (Supplementary Fig. 1A). Long course RT alone
was less frequently advocated over time (4.5% vs 3.1% vs 2.8%,
p¼ 0.0051). CRT decreased during the second timeframe and
increased during the third one (88.9% vs 76.2% vs 80.6%), and al-
ways represented the most used modality. (Supplementary Fig. 2).
In terms of tumor height, the rate of patients receiving preop-
erative therapy for cancer of the upper third (15-11 cm) increased
over time, being 31.5%, 34.5%, and 38.6% in period I, II and III
(p¼ 0.0018) (Fig. 1). Radiological stage I tumors treated with neo-
adjuvant treatment decreased over time (26% vs 10.1% vs 3.3%,
p< 0.0001), whereas the rates of stage II remained stable (48.2% vs
52.2% vs 48.7%, p¼ 0.89). Stage III patients receiving neoadjuvant
treatment significantly increased over time (73.1% vs 80.6% vs
82.5%, p< 0.0001). There was an increasing use of pre-treatment
MRI (88.1% vs 95.2% vs 96.3%, p< 0.0001). More advanced MRcT
and MRcN were observed in more recent timeframes.
Pathological outcome of neoadjuvant treatment
Complete pathological regression was achieved in 15.7% of pa-
tients, whereas 6.6% had no response. We observed an increasing
trend over the three timeframes (15.6% vs 16% vs 18.5%;
p¼ 0.0093). pNx and pN0 were increasingly observed during time
compared with pN1-2 (70.6% vs 71.9% vs 72.9%, p¼ 0.009).
The involved CRM after neoadjuvant treatment decreased over
time (8.2% vs 7.3% vs 5.5%, p ¼ 0.0004). The same occurred in pa-
tients who did not receive preoperative treatment (10.7% vs 8.5% vs
4.6%, p < 0.0001). In patients with cancer of the distal rectum, the
risk of þve CRM was significantly reduced by neoadjuvant treat-
ment over the three timeframes (OR 0.71, 0.59e0.87, Cochran-
Mantel-Haenszel P ¼ 0.0008). However, no significant differences
were observed comparing all patients who received vs those who
did not receive neoadjuvant treatment in the three different
timeframes (OR 0.88, 0.64e1.20, Cochrane-Mantel-Haenszel
P ¼ 0.42).
The median number of nodes retrieved on the specimen was
lower after neoadjuvant treatment compared with no neoadjuvant
treatment (12 [0e100] vs 15 [0e150], p< 0.0001), with no signifi-
cant differences in positive node ratio. Trends were stable over time
(Table 1).
Postoperative treatment
Up to 76.4% of patients that received neoadjuvant treatment,
also received postoperative treatment (Supplementary Fig. 1B).
Most ypN0 patients also received adjuvant therapy in all the
timeframes (72.1% vs 73% vs 69.7%, p¼ 0.262).Please cite this article as: Pellino G et al., Trends and outcome of neoadju
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Factors associated with the use of neoadjuvant treatment
included threatenedMRF (OR 1.285, 95%CI 1.038e1.592, p¼ 0.022);
tumor location, being 5 times higher for tumors of the lower third
(OR 5.222, 95%CI 4.234e6.440, p< 0.0001, advanced MRcT and
MRcN stage. Female gender and advanced age (>65 year-of-age)
were associated with lower use of neoadjuvant treatment (Table 2).
Factors associated with the use of adjuvant treatment included
preoperative treatment (OR 6.316, 95%CI 5.705e6.992, p< 0.0001),
perioperative complications (OR 1.694, 95%CI 1.544e1.858,
p< 0.0001), as well as pT and pN stage. Again, female gender and
age >65 years were associated with lower use of adjuvant treat-
ment, along with cancers of the middle and lower rectum (Table 3).
Disease-free survival, cancer-specific and overall survival after
neoadjuvant treatment over time
Overall, OS was significantly improved in timeframes
2006e2009 and 2010e2013 either with or without preoperative
treatment (p< 0.0001), whereas CSS survival significantly
improved in patients who did not receive neoadjuvant treatment
(Table 4). LR and DFS did not differ.
When considering tumor height, the benefits of neoadjuvant
treatment in terms of LR tended to bemore evident in patients with
cancer of the lower third (p¼ 0.144). CSS and OS were improved
after neoadjuvant treatment, but patients with high rectal cancer
had little benefit (p< 0.0001) (Suppl. Figure 3 and Suppl. Figure 4).
In patients with radiological stage III rectal cancer, preoperative
treatment was associated with significantly longer LR free survival
(p < 0.0001), CSS (p < 0.0001) and OS (p < 0.0001) in both time-
frames. These differences are particularly relevant in MRcN2 pa-
tients. A trend towards an improved DFS was observed with
neoadjuvant treatment in Stage III and MRcN þ ve patients
(Suppl. Figure 3).
Discussion
In this national registry, despite a wider use of MRI as staging
tool, which currently defines the risk factors for a more selective
approach, preoperative therapy has been consistently used and
slightly increased over time. Patients with advanced locoregional
stages such as a deep penetration into the mesorectal space,
threatened or involved MRF, extramural vascular invasion or
extensive nodal involvement are in general considered at risk and
neoadjuvant treatment is recommended. After 2010, approximately
62.5% of all patients underwent preoperative treatment. This po-
tential overuse was particularly detected in patients with upper
rectal cancer, where the use of preoperative treatment can be more
contentious [17]. The CSS benefit was more apparent in cancers of
the lower third, whereas omitting preoperative treatment would
have not affected much the survival of those with upper third
cancers (Fig. 2). Neoadjuvant treatment has significantly improved
the outcome in terms of local disease control. These benefits must
be weighed against undesired side effects [6]. The EURECCA con-
sortium compared the rates of preoperative treatment for rectal
cancer among five different European countries between 2008 and
2009, and found significant variation, ranging between 28% and
86% [18]. The highest rates were found in the Nederland. Following
on this report, the Dutch Surgical Colorectal Cancer Audit Group
performed a critical appraisal on the use of RT in Nederland [19].
After publication of the revised national guidelines in 2014, the use
of RT decreased by 32.8%, 43.5% and 31.6% for cT1N0, cT2N0 and
cT3N0 stage, respectively [19]. In the present series, we observed anvant treatment for rectal cancer: A retrospective analysis and critical
anish Rectal Cancer Project, European Journal of Surgical Oncology,
Table 1
Demographic and multimodal therapy details for patients treated in three timeframes.
Variable 2006e2009 (n¼ 2923) 2010e2013 (n¼ 7370) 2014e2017 (n¼ 4098) P value
Age, years 69 (23e95) 69 (22e100) 68 (21e94) 0.646
Female gender 985 (33.7) 2505 (34) 1465 (35.7) 0.06
ASA score: 0.0001
- I 171 (5.9) 442 (6.0) 277 (6.8)
- II 1601 (54.8) 3904 (53) 2079 (50.7)
- III 1057 (36.2) 2756 (37.4) 1641 (40)
- IV 94 (3.2) 268 (3.6) 101 (2.5)
Tumor height 0.018
- 11e15 cm 718 (24.6) 1749 (23.7) 1035 (25.3)
- 7e10 cm 1051 (36) 2838 (38.5) 1583 (38.6)
- 0e6 cm 1154 (39.5) 2783 (37.8) 1480 (36.1)
MRcT: < 0.0001*
- T0 22 (0.8) 43 (0.6) 36 (0.9)
- T1 288 (9.9) 125 (1.7) 59 (1.4)
- T2 1107 (37.9) 1354 (18.4) 803 (19.6)
- T3 827 (28.3) 4136 (56.1) 2333 (56.9)
- T4 120 (4.1) 912 (12.4) 497 (12.1)
- Missing 559 (19.1) 800 (10.9) 370 (9.0)
MRcN: 0.003*
- N0 803 (27.5) 2161 (29.3) 1158 (28.3)
- N1 940 (32.2) 2491 (33.8) 1420 (34.7)
- N2 621 (21.2) 1918 (26) 1150 (28.1)
- Missing 559 (19.1) 800 (10.9) 370 (9.0)
Radiological Stage: < 0.0001*
- I 617 (21.1) 1070 (14.5) 514 (12.5)
- II 398 (13.6) 1288 (17.5) 620 (15.1)
- III 1786 (61.1) 4658 (63.2) 2663 (65.0)
- not formally stated 132 (4.2) 354 (4.9) 301 (7.3)
Neoadjuvant treatment 1701 (58.2) 4603 (62.5) 2567 (62.6) < 0.0001
- Long course RT 76 (4.5) 141 (3.1) 72 (2.8)
- Long course CRT 1512 (88.9) 3509 (76.2) 2067 (80.6)
- ChT 14 (0.8) 60 (1.3) 19 (0.7)
- Short Course RT± ChT 80 (4.7) 434 (9.4) 160 (6.2)
- ChT followed by RT 19 (1.1) 443 (9.6) 138 (5.4)
- other - () 16 (0.3) 111 (4.3)
Perforation 131 (4.5) 298 (4.0) 185 (4.5) 0.053
Adjuvant treatment 1788 (61.2) 4545 (61.7) 2087 (50.9) < 0.0001
ypT: in 1701 patients in 4603 patients in 2567 patients < 0.0001*
- Tx 52 (3.1) 95 (2.1) 23 (0.9)
- T0 216 (12.7) 619 (13.4) 426 (16.6)
- Tis 17 (1.0) 57 (1.2) 30 (1.2)
- T1 108 (6.3) 237 (5.1) 157 (6.1)
- T2 444 (26.1) 1255 (27.3) 697 (27.2)
- T3 a,b 510 (30) 1554 (33.8) 873 (34)
- T3 c,d 293 (17.2) 528 (11.5) 201 (7.8)
- T4 a 39 (2.3) 136 (3.0) 68 (2.6)
- T4 b 22 (1.3) 106 (2.3) 39 (1.5)
- Missing 0 (0) 16 (0.3) 53 (2.1)
ypN: in 1701 patients in 4603 patients in 2567 patients 0.008*
- Nx 588 (34.6) 1594 (34.6) 840 (32.7)
- N0 612 (36.0) 1705 (37) 995 (38.8)
- N1 342 (20.1) 867 (18.8) 505 (19.7)
- N2 158 (9.3) 421 (9.1) 174 (6.8)
- Missing 0 (0) 16 (0.3) 53 (2.1)
Variable 2006e2009 (n¼ 2923) 2010e2013 (n¼ 7370) 2014e2017 (n¼ 4098) P value
Number of isolated lymph nodes after neoadjuvant treatment 12 (0e58) 12 (0e91) 12 (0e107) 0.791
Distal margin affected after neoadjuvant treatmenta 11 (0.6) 33 (0.7) 17 (0.7) 0.953
CRM affected after neoadjuvant treatmentb 140 (8.2) 336 (7.3) 139 (5.5) 0.0004
Quality of the mesorectum after neoadjuvant treatmentc 0.308
- Complete 1348 (80) 3576 (79.8) 2026 (80.6)
- Nearly complete 237 (14.1) 583 (13) 317 (12.6)
- Incomplete 99 (5.9) 321 (7.2) 171 (6.8)
Data are expressed as number of patients (%) or median (range).
*only including available information.





a 5/1701 missing in 2006e2009; 44/4603 missing in 2010e2013; 53/2567 missing in 2014e2017.
b 1/1701 missing in 2006e2009; 19/4603 missing in 2010e2013; 53/2567 missing in 2014e2017.
c 17/1701 missing in 2006e2009; 123/4603 missing in 2010e2013; 53/2567 missing in 2014e2017.
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Fig. 1. Trends of neoadjuvant treatment over time, according to the height of the tumor. The rate of patients with cancer of the upper third of the rectum increased over time.
Table 2




- Male 1 e e
- Female 0.758 0.648 0.885
Age: < 0.0001
- < 65 year-of-age 1 e e
-  65 year-of-age 0.582 0.498 0.679
Mesorectal fascia threatened 1.285 1.038 1.592 0.022
Sphincter complex involved 1.138 0.766 1.691 0.522
Tumor height: < 0.0001
- 15-11 cm 1 e e
- 7e10 cm 3.304 2.750 3.970
- 0e6 cm 5.222 4.234 6.440
MRcT stage: < 0.0001
- cT1 1 e e
- cT2 2.287 1.503 3.482
- cT3 4.826 3.141 7.415
- cT4 7.951 3.844 16.443
MRcN stage: < 0.0001
- cN0 1 e e
- cN1 5.250 4.430 6.222
- cN2 8.920 7.249 10.977
Timeframe of treatment 0.247
- 2006e2009 1 e e
- 2010e2013 0.882 0.714 1.090
- 2014e2017 1.010 0.774 1.319
MR: magnetic resonance OR: Odds Ratio; 95%CI 95% confidence intervals.
OR>1 associated with increased used of neoadjuvant treatment; statistically sig-
nificant values bold.
Table 3




- Male 1 e e
- Female 0.897 0.816 0.986
Age: < 0.0001
- < 65 year-of-age 1 e e
-  65 year-of-age 0.393 0.357 0.432
Intraoperative perforation 1.011 0.790 1.293 0.932
Tumor height: 0.070
- 15-11 cm 1 e e
- 7e10 cm 0.874 0.773 0.989
- 0e6 cm 0.874 0.770 0.992
Lymph nodes on specimen: 0.832
-  12 1 e e
- < 12 1.022 0.836 1.249
Involved circumferential margin 1.125 0.919 1.377 0.255
Involved distal margin 0.943 0.564 1.578 0.823
pT stage: < 0.0001
- pTx 1 e e
- pT0 1.147 0.761 1.728
- pTis 0.467 0.278 0.785
- pT1 0.579 0.382 0.879
- pT2 0.803 0.542 1.189
- pT3 a.b 1.359 0.916 2.017
- pT3 c.d 1.424 0.942 2.152
- pT4 a 2.013 1.247 3.251
- pT4 b 2.298 1.345 3.928
pN stage: < 0.0001
- pNx 1 e e
- pN0 0.741 0.592 0.928
- pN1 2.748 2.262 3.339
- pN2 2.543 2.006 3.225
Timeframe of treatment 0.744
- 2006e2009 1 e e
- 2010e2013 0.971 0.862 1.094
- 2014e2017 0.949 0.830 1.085
OR: Odds Ratio; 95%CI 95% confidence intervals.
OR>1 associated with increased used of adjuvant treatment; statistically significant
values bold.
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further investigation.
Discrepancies can be observed among the available guidelines
concerning the indications to preoperative treatment [1]. In US, the
trend is to offer widely neoadjuvant treatment based on MRcT and
MRcN. Guidelines from US recommends neoadjuvant treatment in
all patients with any cT3 rectal cancer (including N0),Please cite this article as: Pellino G et al., Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical
assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project, European Journal of Surgical Oncology,
https://doi.org/10.1016/j.ejso.2020.04.056
Table 4
Oncologic outcome according to multimodal treatment for patients operated on in two timeframes with long term follow-up available. Only patients that underwent pre-
operative MRI assessment were included.
Variable 2006e2009 2010e2013 OR (95%CI) P value
Local Recurrence
- No neoadjuvant treatment 33/793 (4.16) 79/2034 (3.88) 1.08 (0.71e1.63) 0.73
- Neoadjuvant treatment 64/1407 (4.54) 145/4099 (3.54) 1.29 (0.96e1.75) 0.09
Distant recurrence
- No neoadjuvant treatment 106/793 (13.37) 227/2034 (11.16) 1.23 (0.96e1.57) 0.10
-Neoadjuvant treatment 197/1407 (14) 588/4099 (14.34) 0.97 (0.82e1.16) 0.75
Death for cancer
-No neoadjuvant treatment 67/793 (8.45) 126/2034 (6.2) 1.39 (1.03e1.90) 0.03
- Neoadjuvant treatment 75/1407 (5.33) 169/4099 (4.12) 1.31 (0.99e1.73) 0.06
Death for any cause
- No neoadjuvant treatment 179/793 (22.57) 288/2034 (14.16) 1.77 (1.44e2.18) < 0.0001
- Neoadjuvant treatment 223/1407 (15.85) 475/4099 (11.59) 1.44 (1.21e1.71) < 0.0001
Data are expressed as number of patients (%). OR>1 favors the time frame 2010e2013 (increased risk for the time frame 2006e2009).
MRI Magnetic Resonance Imaging.
OR Odds Ratio.
95%CI 95% confidence intervals.
Fig. 2. Survival according to MRI N status after surgery alone or with preoperative treatment. Patients with N þ ve disease at MRI had longer local recurrence-free survival after
neoadjuvant treatment (p ¼ 0.001), and longer cancer-specific survival (p < 0.0001), especially those with MRcN2 disease. Even if not significant, disease-free survival seemed to be
longer after preoperative treatment, but this was only observed in MRcN2 patients, suggesting a potential detrimental effect in N -ve individuals.
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However, this is not the case in current European guidelines, in
which selected cT3a/b cancers with minimal penetration into the
mesorectal fat are considered amenable for surgical resection
without preoperative treatment [1e3], even with suspicious nodes
in the mesorectum [3,20,21]. Very recently, the so-called totally-
neoadjuvant treatment (TNT) has been described, consisting of CRT
followed by consolidation chemotherapy [22]. Although TNT has
been associated with reasonable mid-term rates of rectal sparing in
T3/T4 N0/N1 resectable cancers of the distal rectum, the role of
such treatment should be further elucidated [22,23].
The presence of an involved or threatened MRF is the strongest
predictor of LR after curative surgery for rectal cancer, and it should
therefore be used to select patients for neoadjuvant treatment
[20,21]. The most relevant finding of this study is the significant
decrease in þve CRM over time, ranging from 8.2% in the first
timeframe to 7.3% in the second period and 5.5% in the last one. This
positive outcome could be a key achievement of this national
program. On the other hand, the assessment of surgical quality was
based upon the surgical plane defined by the pathologist in the
resected specimen, as mesorectal around 80% across the three
timeframes. Patients who benefited more from preoperative
treatment in terms of R0 resections, were those with cancers
located at the lower rectum. Patients with clinical stage III, partic-
ularly those with N2 lymph nodal involvement, were those to
benefit the most from neoadjuvant treatment in terms of LR, DFS,
CSS and OS. In patients with upper third rectal cancer, the impact of
neoadjuvant treatment on CSS and OS survival was smaller.
The present study found that neoadjuvant treatment was
particularly beneficial for MR-defined stage-III patients, whereas
this effect was questionable or less obvious when assessing MRcT
and in MRcN0 stage alone. Recently, the QuickSilver trial proposed
a combination of MRI-based features to identify patients suitable
for surgery without CRT [24]. The MERCURY II study also recom-
mended MRI assessment of low rectal cancers to reduce over-
treatment and postoperative morbidity [25].
Limitations
This national study has several limitations, mostly derived from
its retrospective analysis. Firstly, datawere uploaded on a voluntary
basis. The agents and dose used for treatment were not recorded.
No data were available concerning the time between the comple-
tion of preoperative treatment and surgery. By spreading over 10
years, the herein reported analyses might have been influenced by
the evolving treatment modalities over time. Lastly, long term
toxicity and specific adverse events of preoperative treatment were
not systematically recorded.
One of the main strengths of the study is the involvement of
many multidisciplinary teams in different centers across the
country in a step-wise educational program onproper TME surgery,
sharing common criteria for radiological and pathology staging as
well as neoadjuvant treatment. The increased performances in
terms of both pathologic and survival outcomes confirmed the
benefits of establishing the registry [11,13e15]. Some policies need
further investigation, especially the management of patients with
cancers of the upper rectum and those with early stages. Additional
MRI-based factors and biomolecular markers [24,26] are likely to
provide more information on the open issues on multimodal
treatment for rectal cancer, and allow the development of a com-
plete prognostic index for treatment individualization [7].
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